Thick XXXX in the elderly.

@entity1 @entity320 @entity1349 @entity66
The objective of this analysis is to ascertain the natural history of elderly @entity1 greater than 65 years of age with thick @entity320 (T4) who were treated with surgery only. Although there are multiple data on elderly @entity1 , there is not a systematic review of survival in elderly @entity1 over 65 years, and with our analysis we tried to enlighten this field in view especially of the growing population of the elderly in the United States. We retrospectively evaluated 112 @entity1 with thick (> or = 4 mm) @entity320 aged 65 or greater. Mean age was 73 years. Mean follow-up was 36 months. The @entity1349 ( @entity1349 ) and disease-free survival (DFS) were 69 and 52 months, respectively. Univariate analysis predicted worse @entity1349 and DFS when @entity1 have positive lymph nodes, high mitotic rate, and increasing thickness. By multivariate analysis, lymph node status was most predictive of @entity1349 and DFS. Lymph node status is the most important prognostic factor in elderly @entity1 with thick @entity320 . Our analysis has shown that elderly @entity1 that received no adjuvant treatment did significantly worse than the historical controls. @entity1 with nodal metastases are candidates for adjuvant therapy. Those without @entity66 constitute a favorable @entity1 group and thus have much better prognosis and may not need adjuvant therapy. However, they must be closely monitored or enrolled in randomized trials. Thus, treatment for @entity320 @entity1 older than 65 should be as aggressive as in younger @entity1 , and these @entity1 should not be denied adjuvant treatment based on their age only.
